ICER Will Explore Value Pricing For Cures In Context Of ‘Shared’ Health System Savings
Future value assessments will include ‘hypothetical’ scenarios in which downstream medical savings will be shared between the health care system and the treatment developer.
You may also be interested in...
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.